AIM:DXRX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. More Details


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Diaceutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DXRX is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: DXRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.


Market Performance


7 Day Return

-1.8%

DXRX

1.4%

GB Life Sciences

-1.5%

GB Market


1 Year Return

42.3%

DXRX

8.4%

GB Life Sciences

-10.7%

GB Market

Return vs Industry: DXRX exceeded the UK Life Sciences industry which returned 7% over the past year.

Return vs Market: DXRX exceeded the UK Market which returned -10% over the past year.


Shareholder returns

DXRXIndustryMarket
7 Day-1.8%1.4%-1.5%
30 Day-2.2%13.8%12.4%
90 Day-25.7%10.0%6.5%
1 Year42.3%42.3%9.0%8.4%-7.2%-10.7%
3 Yearn/a-1.8%-3.2%-0.7%-12.9%
5 Yearn/a36.1%33.6%25.2%-3.5%

Long-Term Price Volatility Vs. Market

How volatile is Diaceutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Diaceutics undervalued compared to its fair value and its price relative to the market?

29.48x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DXRX's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DXRX is good value based on its PE Ratio (29.5x) compared to the GB Life Sciences industry average (62.4x).

PE vs Market: DXRX is poor value based on its PE Ratio (29.5x) compared to the UK market (21.2x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DXRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DXRX is good value based on its PB Ratio (2.7x) compared to the GB Life Sciences industry average (3.8x).


Next Steps

Future Growth

How is Diaceutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

11.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Diaceutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Diaceutics performed over the past 5 years?

39.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DXRX has a high level of non-cash earnings.

Growing Profit Margin: DXRX became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: DXRX's earnings have grown significantly by 39.6% per year over the past 5 years.

Accelerating Growth: DXRX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: DXRX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (30.1%).


Return on Equity

High ROE: DXRX's Return on Equity (7.8%) is considered low.


Next Steps

Financial Health

How is Diaceutics's financial position?


Financial Position Analysis

Short Term Liabilities: DXRX's short term assets (£35.8M) exceed its short term liabilities (£1.6M).

Long Term Liabilities: DXRX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DXRX's debt to equity ratio (0.3%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if DXRX's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: DXRX's debt is well covered by operating cash flow (893.6%).

Interest Coverage: DXRX earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Diaceutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DXRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DXRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DXRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DXRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DXRX's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Peter Keeling (59 yo)

no data

Tenure

Mr. Peter Keeling serves as Chief Executive Officer and Executive Director at Diaceutics PLC. Mr. Keeling was Co-founder and Chief Executive at Diagnology Limited. He has an experience as a leader, entrepr...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Keeling
CEO & Executive Directorno datano data20.82%
£ 23.5m
Philip White
CFO & Executive Directorno datano data3.6%
£ 4.1m
Zarina Bibi
VP & General Counsel1.5yrsno datano data
Amit Jain
MD and Head of Strategy & Corporate Development0.83yrno datano data
Sarah Colgan
Head of Global Marketing0.83yrno datano data
Norma Thompson
Global Head of Human Resources0.17yrno datano data
Damian Thornton
Chief Strategy Officer0.83yrno datano data
Ryan Keeling
Chief Innovation Officer & Executive Directorno datano data3.44%
£ 3.9m
Jordan Clark
Chief Commercial Officer0.83yrno datano data
Sarah Bondi
Head of Strategic Alliances0.83yrno datano data
Susanne Munksted
Chief Precision Officer1.83yrsno datano data
Derek Hosty
VP & Head of Innovation1.25yrsno datano data

0.8yrs

Average Tenure

45yo

Average Age

Experienced Management: DXRX's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.8%.


Top Shareholders

Company Information

Diaceutics PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Diaceutics PLC
  • Ticker: DXRX
  • Exchange: AIM
  • Founded: 2005
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£113.073m
  • Shares outstanding: 84.07m
  • Website: https://www.diaceutics.com

Number of Employees


Location

  • Diaceutics PLC
  • Titanic Suites
  • Enterprise House
  • Belfast
  • County Antrim
  • BT2 8FE
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
7DCDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2019
DXRXAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMar 2019

Biography

Diaceutics Plc provides data, data analytics, and implementation services for pharmaceutical companies worldwide. It offers diagnostic landscape services, such as patient journey, lab mapping, diagnostic r...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/30 19:14
End of Day Share Price2020/11/30 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.